MX2023000570A - Compuestos para el tratamiento de enfermedades neovasculares. - Google Patents
Compuestos para el tratamiento de enfermedades neovasculares.Info
- Publication number
- MX2023000570A MX2023000570A MX2023000570A MX2023000570A MX2023000570A MX 2023000570 A MX2023000570 A MX 2023000570A MX 2023000570 A MX2023000570 A MX 2023000570A MX 2023000570 A MX2023000570 A MX 2023000570A MX 2023000570 A MX2023000570 A MX 2023000570A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazol
- derivatives
- methyl
- treatment
- neovascular diseases
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- -1 1-methyl-1h-pyrazol-3-yl Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012261 overproduction Methods 0.000 abstract 1
- 230000001023 pro-angiogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen tratamientos antiangiogénicos y compuestos para su uso en tratamientos antiangiogénicos, particularmente de afecciones asociadas con angiogénesis anormal o sobreproducción anormal de isoformas proangiogénicas de VEGFxxx en o sobre el ojo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010829.6A GB202010829D0 (en) | 2020-07-14 | 2020-07-14 | Compounds for treatment of neovascular diseases |
| PCT/GB2021/051810 WO2022013555A1 (en) | 2020-07-14 | 2021-07-14 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000570A true MX2023000570A (es) | 2023-04-19 |
Family
ID=72139988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000570A MX2023000570A (es) | 2020-07-14 | 2021-07-14 | Compuestos para el tratamiento de enfermedades neovasculares. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12024504B2 (es) |
| EP (1) | EP4182311B1 (es) |
| JP (1) | JP2023535157A (es) |
| KR (1) | KR20230052890A (es) |
| CN (1) | CN116075506B (es) |
| AU (1) | AU2021309894A1 (es) |
| BR (1) | BR112023000571A2 (es) |
| CA (1) | CA3183466A1 (es) |
| DK (1) | DK4182311T3 (es) |
| ES (1) | ES3039003T3 (es) |
| FI (1) | FI4182311T3 (es) |
| GB (1) | GB202010829D0 (es) |
| HR (1) | HRP20250955T1 (es) |
| HU (1) | HUE072558T2 (es) |
| LT (1) | LT4182311T (es) |
| MX (1) | MX2023000570A (es) |
| PL (1) | PL4182311T3 (es) |
| PT (1) | PT4182311T (es) |
| RS (1) | RS67158B1 (es) |
| SI (1) | SI4182311T1 (es) |
| SM (1) | SMT202500307T1 (es) |
| WO (1) | WO2022013555A1 (es) |
| ZA (1) | ZA202301105B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| CN120917015A (zh) * | 2023-01-20 | 2025-11-07 | 元启(苏州)生物制药有限公司 | Srpk1抑制剂和使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012105A2 (en) | 2001-08-01 | 2003-02-13 | University Of Bristol | Vegf isoform |
| KR101122708B1 (ko) | 2003-12-26 | 2012-03-26 | 마사토시 하기와라 | Ｓｒ 단백질 인산화 제어 방법, 및 유효성분으로서 ｓｒ 단백질 활성 제어제를 함유하는 항바이러스제 |
| JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| WO2010058227A2 (en) | 2008-11-22 | 2010-05-27 | The University Of Bristol | NOVEL USES OF VEGFxxxB |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| US10301264B2 (en) | 2012-10-17 | 2019-05-28 | The University Of Nottingham | Compounds useful for treating ocular neovasculan |
| GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
| JOP20170147B1 (ar) * | 2016-07-07 | 2021-08-17 | Salvat Lab Sa | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة |
| US11420969B2 (en) | 2017-09-27 | 2022-08-23 | Exonate Limited | SRPK1 inhibitors |
| WO2019064512A1 (ja) | 2017-09-29 | 2019-04-04 | 株式会社日立産機システム | データ取得方法、インバータ、及び回転電機 |
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
-
2020
- 2020-07-14 GB GBGB2010829.6A patent/GB202010829D0/en not_active Ceased
-
2021
- 2021-07-14 PL PL21748927.7T patent/PL4182311T3/pl unknown
- 2021-07-14 KR KR1020237005137A patent/KR20230052890A/ko active Pending
- 2021-07-14 JP JP2023502982A patent/JP2023535157A/ja active Pending
- 2021-07-14 HU HUE21748927A patent/HUE072558T2/hu unknown
- 2021-07-14 LT LTEPPCT/GB2021/051810T patent/LT4182311T/lt unknown
- 2021-07-14 BR BR112023000571A patent/BR112023000571A2/pt unknown
- 2021-07-14 EP EP21748927.7A patent/EP4182311B1/en active Active
- 2021-07-14 WO PCT/GB2021/051810 patent/WO2022013555A1/en not_active Ceased
- 2021-07-14 FI FIEP21748927.7T patent/FI4182311T3/fi active
- 2021-07-14 ES ES21748927T patent/ES3039003T3/es active Active
- 2021-07-14 SM SM20250307T patent/SMT202500307T1/it unknown
- 2021-07-14 AU AU2021309894A patent/AU2021309894A1/en active Pending
- 2021-07-14 HR HRP20250955TT patent/HRP20250955T1/hr unknown
- 2021-07-14 RS RS20250853A patent/RS67158B1/sr unknown
- 2021-07-14 PT PT217489277T patent/PT4182311T/pt unknown
- 2021-07-14 MX MX2023000570A patent/MX2023000570A/es unknown
- 2021-07-14 SI SI202130341T patent/SI4182311T1/sl unknown
- 2021-07-14 CA CA3183466A patent/CA3183466A1/en active Pending
- 2021-07-14 DK DK21748927.7T patent/DK4182311T3/da active
- 2021-07-14 CN CN202180049067.2A patent/CN116075506B/zh active Active
-
2022
- 2022-08-03 US US17/817,136 patent/US12024504B2/en active Active
-
2023
- 2023-01-26 ZA ZA2023/01105A patent/ZA202301105B/en unknown
-
2024
- 2024-03-13 US US18/603,489 patent/US20240300929A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230052890A (ko) | 2023-04-20 |
| DK4182311T3 (da) | 2025-08-25 |
| LT4182311T (lt) | 2025-09-25 |
| SI4182311T1 (sl) | 2025-11-28 |
| ZA202301105B (en) | 2025-07-30 |
| BR112023000571A2 (pt) | 2023-01-31 |
| US20240300929A1 (en) | 2024-09-12 |
| RS67158B1 (sr) | 2025-09-30 |
| WO2022013555A1 (en) | 2022-01-20 |
| US12024504B2 (en) | 2024-07-02 |
| ES3039003T3 (en) | 2025-10-16 |
| SMT202500307T1 (it) | 2025-11-10 |
| AU2021309894A1 (en) | 2023-03-09 |
| PT4182311T (pt) | 2025-08-27 |
| FI4182311T3 (fi) | 2025-08-22 |
| JP2023535157A (ja) | 2023-08-16 |
| US20220411412A1 (en) | 2022-12-29 |
| EP4182311A1 (en) | 2023-05-24 |
| PL4182311T3 (pl) | 2025-11-12 |
| HRP20250955T1 (hr) | 2025-10-10 |
| CN116075506B (zh) | 2025-10-10 |
| GB202010829D0 (en) | 2020-08-26 |
| HUE072558T2 (hu) | 2025-11-28 |
| CN116075506A (zh) | 2023-05-05 |
| CA3183466A1 (en) | 2022-01-20 |
| EP4182311B1 (en) | 2025-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202301105B (en) | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases | |
| WO2019209962A8 (en) | Compounds and uses thereof | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2022001075A (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| MX2020009942A (es) | Compuestos y usos de los mismos. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| WO2019209948A8 (en) | Compounds and uses thereof | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| WO2020154571A8 (en) | Compounds and uses thereof | |
| BR112017019437A2 (pt) | terapias para câncer | |
| MX2018005352A (es) | Metodos y composiciones para el tratamiento de amiloidosis. | |
| CL2020001888A1 (es) | Terapia de combinación para tratar o prevenir el cáncer. | |
| MX2022002751A (es) | Tratamiento de la abstinencia de opioides. | |
| PH12018502318A1 (en) | Compositions and methods for treatment of inflammation of infection of the eye | |
| BR112022004801A2 (pt) | Carboxamidas de benzimidazol substituídas e seu uso no tratamento de distúrbios médicos | |
| PT4031117T (pt) | Mutante do ngf para utilização no tratamento ou prevenção de distúrbios oftálmicos | |
| AU2017258649A1 (en) | Covalent BTK inhibitors and uses thereof | |
| BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| MX2019014771A (es) | Inhibidores de la proteína -1 de adhesión vascular para uso en la prevención o tratamiento de migraña. |